ZULIAN, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 6.023
AS - Asia 458
EU - Europa 453
AF - Africa 4
OC - Oceania 1
Totale 6.939
Nazione #
US - Stati Uniti d'America 6.019
CN - Cina 361
IT - Italia 152
FI - Finlandia 93
VN - Vietnam 66
DE - Germania 54
GB - Regno Unito 50
SE - Svezia 36
UA - Ucraina 36
IN - India 23
IE - Irlanda 11
FR - Francia 6
EG - Egitto 4
HK - Hong Kong 4
NL - Olanda 4
RU - Federazione Russa 4
CA - Canada 3
CH - Svizzera 2
RO - Romania 2
DK - Danimarca 1
GR - Grecia 1
ID - Indonesia 1
JP - Giappone 1
MX - Messico 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SG - Singapore 1
SI - Slovenia 1
Totale 6.939
Città #
Fairfield 1.302
Woodbridge 601
Houston 558
Ashburn 512
Cambridge 442
Seattle 433
Wilmington 389
Chandler 286
Ann Arbor 285
Jacksonville 161
Princeton 159
San Diego 140
Medford 123
Beijing 116
Des Moines 88
Dong Ket 66
Helsinki 63
Roxbury 50
Nanjing 44
Padova 31
Jinan 24
London 23
Hebei 21
Nanchang 19
Boardman 15
Norwalk 14
Shenyang 13
Ningbo 12
Changsha 11
Dublin 11
Guangzhou 11
Borås 7
Kharkiv 7
Ogden 7
Tianjin 7
Zhengzhou 7
Pune 6
Bologna 5
Haikou 5
Jiaxing 5
Kilburn 5
Lanzhou 5
Fuzhou 4
Hong Kong 4
Las Vegas 4
New York 4
Taiyuan 4
Coimbatore 3
Grado 3
McKinney 3
Rome 3
Albignasego 2
Bari 2
Cairo 2
Cape Coral 2
Caprino Veronese 2
Cebazat 2
Cupra Marittima 2
Ferrara 2
Frankfurt am Main 2
Hangzhou 2
Hounslow 2
Lappeenranta 2
Naples 2
New Delhi 2
Noale 2
Nürnberg 2
Prescot 2
Qina 2
San Francisco 2
Shanghai 2
Southwark 2
Udine 2
Washington 2
Yellow Springs 2
Amsterdam 1
Bagno A Ripoli 1
Barga 1
Bassano del Grappa 1
Bengaluru 1
Berlin 1
Brendola 1
Cerveteri 1
Chicago 1
Chiswick 1
Dalsjoefors 1
Enschede 1
Falkenstein 1
Falls Church 1
Foggia 1
Gavardo 1
Geislingen an der Steige 1
Gilroy 1
Greenwich 1
Hefei 1
Indiana 1
Islington 1
Lawrenceville 1
Los Angeles 1
Mexico City 1
Totale 6.194
Nome #
A new computerized method for the assessment of skin lesions in Localized Scleroderma 144
Consensus-based recommendations for the management of juvenile localised scleroderma 125
Synovial hemangioma of infrapatellar (Hoffa) fat pad: Magnetic resonance imaging and ultrasound features 111
Anti-DFS70 antibodies in healthy schoolchildren: A follow-up analysis 106
Severe clinical course of systemic lupus erythematosus in the first year of life 100
CXCR6-CXCL16 interaction in the pathogenesis of Juvenile Idiopathic Arthritis. 100
Congenital localized scleroderma 99
Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis 96
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised, double-blind withdrawal trial 90
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 89
Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis 87
A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea) 85
Update of EULAR recommendations for the treatment of systemic sclerosis 84
Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review 84
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study 83
Localized scleroderma of the face 82
Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases - a multicentre prospective study 80
Musculoskeletal pain in schoolchildren across puberty: A 3-year follow-up study 80
Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. 79
The European network for care of children with paediatric rheumatic diseases: care across borders 78
CXCR3/CXCL10 expression in the synovium of children with juvenile idiopathic arthritis 76
Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. 74
Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial 74
Recent advances in the management of juvenile systemic sclerosis 74
A computerized method to assess the skin involvement in localized scleroderma. 73
The pediatric rheumatology European Society American College of Rheumatology European league against rheumatism provisional classification criteria for juvenile systemic sclerosis 73
Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes 72
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 71
THU0532 RITUXIMAB FOR RAPIDLY PROGRESSIVE JUVENILE SYSTEMIC SCLEROSIS 71
CXCL10/CXCR3 interaction mediate chemotaxis of T cell into the synovium of children with oligoarticular juvenile idiopathic arthritis. 71
Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis 70
Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma 68
Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients 67
Early predictors at severe course of uveitis in oligoarticular Juvenile idiopathic arthritis 66
Sarcopenia in juvenile localized scleroderma: new insights on deep involvement 64
Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro 64
Prevalence of antinuclear antibodies in schoolchildren during puberty and possible relationship with musculoskeletal pain: A longitudinal study 63
Successful treatment of gangrene in systemic necrotizing vasculitis with iloprost 63
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 62
Otolaryngological manifestations of rheumatic diseases in children. 61
Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy. 61
The 1982 ARA/ACR criteria for theclassification of systemic lupus erythematosus in pediatric and adult patients 61
Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis 60
Monoarticular juvenile chronic arthritis of the shoulder: Report of a case and review of the literature 59
Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry 59
Bone involvement as presenting sign of pediatric-onset Gaucher disease 58
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis 58
Periodic fevers with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) 57
Clinical features and outcome of cogan syndrome 56
Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography 56
A preliminary disease severity score for juvenile systemic sclerosis 56
Case of the month: A five-year-old girl with intractable arthralgias 55
Immunopathogenesis of pediatric localized scleroderma 55
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate 55
Prolactin receptor levels on lymphocytes vary with menstrual cycle in women 54
Infrared thermography in children: A reliable tool for differential diagnosis of peripheral microvascular dysfunction and Raynaud's phenomenon? 54
Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis 53
Joint hypermobility and oligoarticular juvenile idiopathic arthritis: What relationship? 53
Psychological profile in children and adolescents with severe course Juvenile idiopathic arthritis 53
Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review 53
Consensus-based recommendations for the management of juvenile systemic sclerosis 53
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra 52
Reflex sympathetic dystrophy in children 52
Acquired strabismus in linear scleroderma of the face 52
Systemic Sclerosis and Localized Scleroderma in Childhood 52
Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis 51
Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database 51
La porpora di Schonlein-Henoch 50
Cone beam computed tomography for the assessment of linear scleroderma of the face 50
Is there a role for arthroscopic synovectomy in oligoarticular juvenile idiopathic arthritis? 49
CXCL10/CXCR3 interaction mediate chemotaxis of T cell into the synovium of children with oligoarticular juvenile idiopathic arthritis. 49
Juvenile idiopathic arthritis: Current and future treatment options 49
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children 49
Immunopathogenesis of juvenile systemic sclerosis 49
Methotrexate in Linear Scleroderma: long-term efficacy in 50 children from a single Pediatric Rheumatology Centre 48
Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma 48
Outcome measures and medical progress: why outcome measures are needed in childhood arthritis 47
Methotrexate: New uses for an old drug 47
Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: Data from the Eustar database 47
Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis 47
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 46
New developments in localized scleroderma 45
Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: An international collaboration 45
Methotrexate in juvenile idiopathic arthritis: Advice and recommendations from the MARAJIA expert consensus meeting 45
Disease-free interval as predictor of relapsy in early onset pauciarticular juvenile chronic arthritis 43
Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial 43
Long-term clinical Profile of children with the low-penetrance R92Q mutation of the tNFRSF1A gene 42
Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population 42
The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age 42
Long-Term Methotrexate Efficacy in Juvenile Localized Scleroderma 41
Rituximab for rapidly progressive juvenile systemic sclerosis 41
Disease-free interval as predictor of relapsy of uveitis in early onset pauciarticular juvenile chronic arthritis 40
Localized scleroderma 40
Responsiveness of outcome measures in juvenile chronic arthritis 40
Case Report: Life-Threatening Macrophage Activation Syndrome With Fulminant Myocarditis Successfully Rescued by High Dose Intravenous Anakinra 40
Early echocardiographic and cardiac mri findings in multisystem inflammatory syndrome in children 40
Treatment in Juvenile Scleroderma 38
Concomitant severe Kawasaki disease and pityriasis rubra pilaris in a teenager: just a coincidence? 37
Scleroderma in children: An update 36
Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: Pathogenetic and clinical implications 36
Totale 6.199
Categoria #
all - tutte 28.280
article - articoli 26.812
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 202
Totale 55.294


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019319 0 0 0 0 0 0 0 0 0 55 147 117
2019/20201.779 129 64 11 59 96 68 83 110 469 340 192 158
2020/20211.754 119 218 115 137 170 56 29 185 254 130 228 113
2021/20221.666 56 192 176 129 93 60 83 166 212 36 122 341
2022/2023803 234 44 22 50 122 110 9 52 96 14 41 9
2023/2024403 21 75 69 36 57 33 52 24 27 9 0 0
Totale 7.124